References
- Auriacombe S, Pere J-J, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129–s38
- McRae T, Schwam E. Comments on efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18(6):i–iii
- Auriacombe S, Pere J-J, Rivage Study Group. Response to comments on efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18(6):iv–vi
- Rogers S, Farlow M, Doody R, Mohs R, Friedhoff L. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50: 136–45
- Rogers S, Doody R, Mohs R, Friedhoff L. Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 1998;158:1021–31